Guardant Health (GH) Investor Day 2025 summary

Strategic vision and innovation

• Introduced the Smart Platform and Infinity AI, enabling multimodal data integration and rapid product innovation across genomics, epigenomics, oncology, screening, and multi-disease applications.

• Expanded Shield from CRC to multi-cancer detection, leveraging a vast biobank of over 1M patient samples, AI, and real-world data for accelerated evidence generation and regulatory advancement.

• Announced Guardant Reveal Ultra, an ultrasensitive tissue-informed MRD test with 1ppm sensitivity, addressing unmet needs in cancer monitoring.

• Strategic collaborations with Quest Diagnostics, Pfizer, and AstraZeneca expand access, accelerate clinical utility studies, and support innovation in companion diagnostics.

• Shield received FDA approval, ADLT status, and NCCN guideline inclusion, establishing a strong foundation for growth and broader disease screening.

Financial guidance and growth outlook

• 2028 revenue target raised to ~$2.2B, reflecting a 34% CAGR from 2025, with growth across oncology, biopharma, and screening segments.

• Free cash flow breakeven accelerated to Q4 2027, 12 months ahead of previous guidance.

• 2025 revenue guidance set at $915M–$925M, with oncology, biopharma, and screening all contributing.

• Oncology revenue expected to reach $1.4B in 2028, with continued ASP expansion and volume growth across Guardant360, Tissue, and Reveal products.

• Shield screening revenue projected to exceed $500M in 2028, with ASP target increased to $700 and gross margin improvements from COGS reductions; gross margin expected to improve to 65–70% by 2028.

Commercial execution and market expansion

• Achieved rapid adoption of Shield, with >90% adherence and strong uptake among previously unscreened populations, supported by national guideline inclusion and Medicare coverage.

• Built a field force of 250+ reps in 2025, targeting 600–700 by 2028, and expanded digital and EMR integrations to streamline ordering and access.

• Secured major payer coverage and legislative wins, ensuring access for over 310 million Americans and driving ASP improvements across the portfolio.

• International expansion advanced through public-private partnerships and reimbursement wins in Europe, Japan, and the Middle East.

• AI-driven efficiencies and operational improvements across technology, sales, and operations are accelerating path to profitability and supporting sustainable growth.